Document is current
Any future updates will be listed below
-
Authors
Hitchings, Matt D. T. https://orcid.org/0000-0003-2327-3557
Huang, Angkana T. https://orcid.org/0000-0002-9857-3506
Ranzani, Otavio T. https://orcid.org/0000-0002-4677-6862
García-Carreras, Bernardo https://orcid.org/0000-0002-0714-300X
Nogueira, Mauricio L. https://orcid.org/0000-0003-1102-2419
Ko, Albert I. https://orcid.org/0000-0001-9023-2339
Croda, Julio
Salje, Henrik https://orcid.org/0000-0003-3626-4254
Cummings, Derek A. T.
- License Information
-
More Information
Article History
Received: 29 May 2025
Accepted: 22 January 2026
First Online: 6 February 2026
Competing interests
: M.D.T.H. and B.C.G. report a contract from Merck, Sharp, and Dohme (MSD) (to the University of Florida) for research unrelated to this article. MLN received funding from Butantan and Valneva regarding arbovirus vaccines. AIK reports research grants from Takeda and is a scientific advisory board member for the dengue vaccine program at MSD, an expert panel member for the Reckitt Global Hygiene Institute, and a Board of Directors member (unpaid) of the American Society of Tropical Medicine and Hygiene. JC received funding from Sanofi, MSD, Bill and Melinda Gates Foundation, Valneva/Butantan, Takeda Pharmaceuticals International AG, and payment/honoraria from Foro Latinoamericano para Asesores Médicos en Vacunas 2023 (Pfizer), Pfizer Emerging Markets Advance Speaker Training 2024 (Pfizer). Also, J.C. is on the Brazil advisory board for mRNA−1273 vaccine (Modern/Zodiac), RSV maternal vaccine (Pfizer) and Qdenga vaccine (TAK-003), and holds a position on the Takeda Global Dengue Steering Committee and has received honoraria for speaking at Takeda symposia. HS reports a contract from MSD (to the University of Cambridge) for research unrelated to this article. DATC reports contracts from MSD and from Pfizer (to the University of Florida and to Johns Hopkins University) for research unrelated to this article.
